Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RQC for Preventing Progression in Age-Related Macular Degeneration
NCT05062486Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Nov 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of resveratrol, quercetin in age-related macular degeneration (AMD). Started Oct 2021; status: completed.
02
Drugs
resveratrolquercetin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05062486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062486.